Antitumor efficacy induced by the three CTLA4 antagonists with or without anti-PD-1 was assessed in the syngeneic CT26 colon carcinoma tumor model (figure 5) as well as in MB49 and MC38 tumor models (online supplemental figure 4). The gene discussed is CTLA4; the disease is neoplasm.